ArticleNature medicine2013
Quantitative imaging of disease signatures through radioactive decay signal conversion.
Article in Nature medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
74 citing papers in PubMed.
- NIS-Centered Reporter Gene Imaging and Radionuclide-Integrated Nanoplatforms for Quantitative Tracking of Immune Cell Therapy in Oncology and Inflammatory Disease Models.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Article
- Improved X-ray absorption capability of Core-shell nano-transducer in situ enhances γ-ray-excited radioluminescence imaging in vivo.Journal of nanobiotechnology · 2026Article
- Illumination of Targeting Nanotherapeutics with Precision Eyes: From Optical to Radio-nanotheranostics.Theranostics · 2026Review
- Nanoparticle Detection in Biology and Medicine: A Review.Biosensors · 2025Review
- Cerenkov luminescence microscopy: A novel approach for high-resolution radiotracer imaging.iScience · 2025Article
- Advanced Image-Guidance and Surgical-Navigation Techniques for Real-Time Visualized Surgery.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Multiplexed imaging of radionuclides.Nature biomedical engineering · 2025Review
- Radiances of Cerenkov-Emitting Radionuclides on the In Vivo Imaging System.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- Superluminal Molecular and Nanomaterial Probes Based on Fast Ions or Electrons.Molecules (Basel, Switzerland) · 2024Review
- Amplification of Cerenkov luminescence using semiconducting polymers for cancer theranostics.Advanced functional materials · 2023Article
- Practical Guidance for Developing Small-Molecule Optical Probes for In Vivo Imaging.Molecular imaging and biology · 2023Review
- Detection of Shortwave-Infrared Cerenkov Luminescence from Medical Isotopes.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Article
- Prospective testing of clinical Cerenkov luminescence imaging against standard-of-care nuclear imaging for tumour location.Nature biomedical engineering · 2022Observational
- Sensitivity improved Cerenkov luminescence endoscopy using optimal system parameters.Quantitative imaging in medicine and surgery · 2022Article
- Cerenkov radiation-activated probes for deep cancer theranostics: a review.Theranostics · 2022Review
- Radiopharmaceutical and EuJournal of nanobiotechnology · 2021Article
- Ultrasmall Downconverting Nanoparticle for Enhanced Cerenkov Imaging.Nano letters · 2021Article
- Surgical Advances in Osteosarcoma.Cancers · 2021Review
- A Multilevel Probabilistic Cerenkov Luminescence Tomography Reconstruction Framework Based on Energy Distribution Density Region Scaling.Frontiers in oncology · 2021Article
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
In the era of personalized medicine, there is an urgent need for in vivo techniques able to sensitively detect and quantify molecular activities. Sensitive imaging of gamma rays is widely used; however, radioactive decay is a physical constant, and its signal is independent of biological interactions. Here, we introduce a framework of previously uncharacterized targeted and activatable probes that are excited by a nuclear decay-derived signal to identify and measure molecular signatures of disease. We accomplished this by using Cerenkov luminescence, the light produced by β-particle-emitting radionuclides such as clinical positron emission tomography (PET) tracers. Disease markers were detected using nanoparticles to produce secondary Cerenkov-induced fluorescence. This approach reduces background signal compared to conventional fluorescence imaging. In addition to tumor identification from a conventional PET scan, we demonstrate the medical utility of our approach by quantitatively determining prognostically relevant enzymatic activity. This technique can be applied to monitor other markers and represents a shift toward activatable nuclear medicine agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.